Barry Littlejohns is the current President of Biologics & Specialty Drug Delivery at Catalent. Prior to this, they served as the Senior Vice President of Operations at Genmab from July 2009 to July 2010. Genmab is a Danish company dedicated to creating and developing human antibodies, with a focus on Oncology. Barry was responsible for global operations at Genmab, overseeing manufacturing, CMC, quality, and preclinical and clinical operations.
From January 2009 to July 2009, Barry Littlejohns served as the Vice President of Global Business Operations at Catalent Pharma Solutions. Catalent Pharma Solutions is a leading provider of manufacturing and packaging services for the pharmaceutical industry with 30 facilities in 12 countries and 9,400 employees. In this role, Barry was responsible for managing all indirect and SG&A expenses through an Indirect Bullet Train Program. Barry developed and implemented systems, processes and initiatives that generated cash savings of $25 million in the first year. Barry also established a framework of 35 Indirect Leaders throughout the organization and set up systems and processes to manage projects in all countries and functions.
Barry Littlejohns has a degree in finance from the University of Derby and an HND in business and finance from Swindon College.
They are on a team with Tom Castellano - SVP, CFO, Karen Santiago - VP & Chief Accounting Officer, and Charles Lickfold - SVP & CIO. Barry Littlejohns reports to Alessandro Maselli, President, CEO & Board Member.
Current role